What About the Ebola Vaccine
The Ebola-vaccine was developed by the Public Health Agency of Canada, licensed to NewLink Genetics, who in turn licensed it to Merck and Co Inc.
The Ebola-vaccine works by replacing a gene from a harmless virus known as vesicular stomatitis virus with a gene encoding an Ebola virus surface protein. The Ebola-vaccine does not contain the live Ebola virus.
The trial Ebola-vaccine was named Ebola ça Suffit, French for Ebola that's enough. The early trials of the NewLink Genetics and Merck Vaccines USA in
"The estimated Ebola-vaccine efficacy was 100 percent," a team of researchers say.The vaccine is administered via a shot to the upper arm. The researchers who ran the trial say their results suggest a single injection is highly effective, and that protection against Ebola can be established quickly. They're also still analyzing possible adverse reactions to the drug.